Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Латентный аутоиммунный диабет – сахарный диабет 1,5 типа?
Латентный аутоиммунный диабет – сахарный диабет 1,5 типа?
Хачатурян Н.Э. Латентный аутоиммунный диабет – сахарный диабет 1,5 типа? CardioСоматика. 2018; 9 (2): 31–35. DOI: 10.26442/2221-7185_2018.2.31-35
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В настоящее время широко изучается один из вариантов течения аутоиммунного сахарного диабета – медленно прогрессирующий аутоиммунный диабет взрослых (латентный аутоимунный диабет взрослых – latent autoimmune diabetes of adults, LADA). Он сопровождается нетипичной клинической картиной как для классического сахарного диабета типа 1, так и для типа 2. Несмотря на наличие положительных аутоантител, LADA характеризуется медленными темпами аутоиммунной деструкции, в связи с чем потребность в инсулинотерапии возникает не сразу. В предлагаемой статье мы попытались разобраться, к какому типу сахарного диабета по своему течению LADA ближе. Также освещается роль самоконтроля гликемии у пациентов с LADA.
Ключевые слова: латентный аутоимунный диабет взрослых, самоконтроль гликемии, сахарный диабет, глюкометр.
Key words: latent autoimmune diabetes of adults, self-control of glycemia, diabetes mellitus, glucometer.
Ключевые слова: латентный аутоимунный диабет взрослых, самоконтроль гликемии, сахарный диабет, глюкометр.
________________________________________________
Key words: latent autoimmune diabetes of adults, self-control of glycemia, diabetes mellitus, glucometer.
Полный текст
Список литературы
1. Глобальный доклад по диабету ВОЗ, 2016. / Global'nyi doklad po diabetu VOZ, 2016. [in Russian]
2. Landin-Olsson M. Latent autoimmune diabetes in adults. Ann NY Acad Sci 2002; 958: 112–6.
3. Leslie RD, Williams R, Pozzilli P. Clinical review: Type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. J Clin Endocrinol Metab 2006; 91 (5): 1654–9.
4. Tuomi T, Groop L, Zimmet PZ, Merrill J et al. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993; 42: 359–62.
5. Tuomi T, Zimmet P, Mackay IR et al. Latent Autoimmune Diabetes Mellitus in Adults (LADA): the Role of Antibodies to Glutamic Acid Decarboxylase in Diagnosis and Prediction of Insulin Dependency. Diabetes 1994; 11: 299–303.
6. Zimmet PZ. The pathogenesis and prevention of diabetes in adults: genes, autoimmunity, and demography. Diabetes Care 1995; 18: 1050–64.
7. Fourlanos S, Perry C, Stein MS et al. A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care 2006; 29 (5): 970–5.
8. Behme MT, Dupre J, Harris SB et al. Insulin resistance in latent autoimmune diabetes of adulthood. Ann NY Acad Sci 2003; 1005: 374–7.
9. Carlsson S, Midthjell K, Tesfamarian M.Y et al. Age, overweight and physical inactivity increase the risk of latent autoimmune diabetes in adults: results from the Nord-Trоndelag health study. Diabetologia 2007; 50 (1): 55–8.
10. Nambam B, Aggarwal S, Jain A. Latent autoimmune diabetes in adults: A distinct but heterogeneous clinical entity. World J Diabetes 2010; 1 (4): 111–5.
11. Thunander M, Thorgeirsson H, Törn C et al. b-cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: a 3-year follow-up. Eur J Endocrinol 2011; 164 (2): 239–45.
12. Maruyama T, Shimada A, Kanatsuka A et al. Multicenter prevention trial of slowly progressive type 1 diabetes with small dose of insulin (the Tokyo study): preliminary report. Ann N Y Acad Sci 2003; 1005: 362–9.
13. Takino H, Yamasaki H, Sera Y et al. The preliminary report from the nation-wide prevention study for type 1 diabetes initially diagnosed as type 2 in Japan. Diabetes Metab Rev 1998; 14: 334–5.
14. Kobayashi T, Nakanishi K, Murase T, Kosaka K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 1996; 45: 622–6.
15. Алгоритмы специализированной медицинской помощи больных сахарным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой. Вып. 8. М., 2017. / Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nykh sakharnym diabetom. Pod red. I.I.Dedova, M.V.Shestakovoi. Vyp. 8. M., 2017. [in Russian]
16. Caswell M et al. Accuracy and User Performance Evaluation of a Blood Glucose Monitoring System. Diabetes Technol Ther 2015; 3: 1–7.
2. Landin-Olsson M. Latent autoimmune diabetes in adults. Ann NY Acad Sci 2002; 958: 112–6.
3. Leslie RD, Williams R, Pozzilli P. Clinical review: Type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. J Clin Endocrinol Metab 2006; 91 (5): 1654–9.
4. Tuomi T, Groop L, Zimmet PZ, Merrill J et al. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993; 42: 359–62.
5. Tuomi T, Zimmet P, Mackay IR et al. Latent Autoimmune Diabetes Mellitus in Adults (LADA): the Role of Antibodies to Glutamic Acid Decarboxylase in Diagnosis and Prediction of Insulin Dependency. Diabetes 1994; 11: 299–303.
6. Zimmet PZ. The pathogenesis and prevention of diabetes in adults: genes, autoimmunity, and demography. Diabetes Care 1995; 18: 1050–64.
7. Fourlanos S, Perry C, Stein MS et al. A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care 2006; 29 (5): 970–5.
8. Behme MT, Dupre J, Harris SB et al. Insulin resistance in latent autoimmune diabetes of adulthood. Ann NY Acad Sci 2003; 1005: 374–7.
9. Carlsson S, Midthjell K, Tesfamarian M.Y et al. Age, overweight and physical inactivity increase the risk of latent autoimmune diabetes in adults: results from the Nord-Trоndelag health study. Diabetologia 2007; 50 (1): 55–8.
10. Nambam B, Aggarwal S, Jain A. Latent autoimmune diabetes in adults: A distinct but heterogeneous clinical entity. World J Diabetes 2010; 1 (4): 111–5.
11. Thunander M, Thorgeirsson H, Törn C et al. b-cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: a 3-year follow-up. Eur J Endocrinol 2011; 164 (2): 239–45.
12. Maruyama T, Shimada A, Kanatsuka A et al. Multicenter prevention trial of slowly progressive type 1 diabetes with small dose of insulin (the Tokyo study): preliminary report. Ann N Y Acad Sci 2003; 1005: 362–9.
13. Takino H, Yamasaki H, Sera Y et al. The preliminary report from the nation-wide prevention study for type 1 diabetes initially diagnosed as type 2 in Japan. Diabetes Metab Rev 1998; 14: 334–5.
14. Kobayashi T, Nakanishi K, Murase T, Kosaka K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 1996; 45: 622–6.
15. Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nykh sakharnym diabetom. Pod red. I.I.Dedova, M.V.Shestakovoi. Vyp. 8. M., 2017. [in Russian]
16. Caswell M et al. Accuracy and User Performance Evaluation of a Blood Glucose Monitoring System. Diabetes Technol Ther 2015; 3: 1–7.
2. Landin-Olsson M. Latent autoimmune diabetes in adults. Ann NY Acad Sci 2002; 958: 112–6.
3. Leslie RD, Williams R, Pozzilli P. Clinical review: Type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. J Clin Endocrinol Metab 2006; 91 (5): 1654–9.
4. Tuomi T, Groop L, Zimmet PZ, Merrill J et al. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993; 42: 359–62.
5. Tuomi T, Zimmet P, Mackay IR et al. Latent Autoimmune Diabetes Mellitus in Adults (LADA): the Role of Antibodies to Glutamic Acid Decarboxylase in Diagnosis and Prediction of Insulin Dependency. Diabetes 1994; 11: 299–303.
6. Zimmet PZ. The pathogenesis and prevention of diabetes in adults: genes, autoimmunity, and demography. Diabetes Care 1995; 18: 1050–64.
7. Fourlanos S, Perry C, Stein MS et al. A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care 2006; 29 (5): 970–5.
8. Behme MT, Dupre J, Harris SB et al. Insulin resistance in latent autoimmune diabetes of adulthood. Ann NY Acad Sci 2003; 1005: 374–7.
9. Carlsson S, Midthjell K, Tesfamarian M.Y et al. Age, overweight and physical inactivity increase the risk of latent autoimmune diabetes in adults: results from the Nord-Trоndelag health study. Diabetologia 2007; 50 (1): 55–8.
10. Nambam B, Aggarwal S, Jain A. Latent autoimmune diabetes in adults: A distinct but heterogeneous clinical entity. World J Diabetes 2010; 1 (4): 111–5.
11. Thunander M, Thorgeirsson H, Törn C et al. b-cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: a 3-year follow-up. Eur J Endocrinol 2011; 164 (2): 239–45.
12. Maruyama T, Shimada A, Kanatsuka A et al. Multicenter prevention trial of slowly progressive type 1 diabetes with small dose of insulin (the Tokyo study): preliminary report. Ann N Y Acad Sci 2003; 1005: 362–9.
13. Takino H, Yamasaki H, Sera Y et al. The preliminary report from the nation-wide prevention study for type 1 diabetes initially diagnosed as type 2 in Japan. Diabetes Metab Rev 1998; 14: 334–5.
14. Kobayashi T, Nakanishi K, Murase T, Kosaka K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 1996; 45: 622–6.
15. Алгоритмы специализированной медицинской помощи больных сахарным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой. Вып. 8. М., 2017. / Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nykh sakharnym diabetom. Pod red. I.I.Dedova, M.V.Shestakovoi. Vyp. 8. M., 2017. [in Russian]
16. Caswell M et al. Accuracy and User Performance Evaluation of a Blood Glucose Monitoring System. Diabetes Technol Ther 2015; 3: 1–7.
________________________________________________
2. Landin-Olsson M. Latent autoimmune diabetes in adults. Ann NY Acad Sci 2002; 958: 112–6.
3. Leslie RD, Williams R, Pozzilli P. Clinical review: Type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. J Clin Endocrinol Metab 2006; 91 (5): 1654–9.
4. Tuomi T, Groop L, Zimmet PZ, Merrill J et al. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993; 42: 359–62.
5. Tuomi T, Zimmet P, Mackay IR et al. Latent Autoimmune Diabetes Mellitus in Adults (LADA): the Role of Antibodies to Glutamic Acid Decarboxylase in Diagnosis and Prediction of Insulin Dependency. Diabetes 1994; 11: 299–303.
6. Zimmet PZ. The pathogenesis and prevention of diabetes in adults: genes, autoimmunity, and demography. Diabetes Care 1995; 18: 1050–64.
7. Fourlanos S, Perry C, Stein MS et al. A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care 2006; 29 (5): 970–5.
8. Behme MT, Dupre J, Harris SB et al. Insulin resistance in latent autoimmune diabetes of adulthood. Ann NY Acad Sci 2003; 1005: 374–7.
9. Carlsson S, Midthjell K, Tesfamarian M.Y et al. Age, overweight and physical inactivity increase the risk of latent autoimmune diabetes in adults: results from the Nord-Trоndelag health study. Diabetologia 2007; 50 (1): 55–8.
10. Nambam B, Aggarwal S, Jain A. Latent autoimmune diabetes in adults: A distinct but heterogeneous clinical entity. World J Diabetes 2010; 1 (4): 111–5.
11. Thunander M, Thorgeirsson H, Törn C et al. b-cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: a 3-year follow-up. Eur J Endocrinol 2011; 164 (2): 239–45.
12. Maruyama T, Shimada A, Kanatsuka A et al. Multicenter prevention trial of slowly progressive type 1 diabetes with small dose of insulin (the Tokyo study): preliminary report. Ann N Y Acad Sci 2003; 1005: 362–9.
13. Takino H, Yamasaki H, Sera Y et al. The preliminary report from the nation-wide prevention study for type 1 diabetes initially diagnosed as type 2 in Japan. Diabetes Metab Rev 1998; 14: 334–5.
14. Kobayashi T, Nakanishi K, Murase T, Kosaka K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 1996; 45: 622–6.
15. Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nykh sakharnym diabetom. Pod red. I.I.Dedova, M.V.Shestakovoi. Vyp. 8. M., 2017. [in Russian]
16. Caswell M et al. Accuracy and User Performance Evaluation of a Blood Glucose Monitoring System. Diabetes Technol Ther 2015; 3: 1–7.
Авторы
Н.Э.Хачатурян
ГБУЗ «Московский клинический научный центр им. А.С.Логинова» Департамента здравоохранения г. Москвы. 111123, Россия, Москва, ш. Энтузиастов, д. 86;
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1
nane18@list.ru
A.S.Loginov Moscow Clinical Scientific Practical Center of the Department of Health of Moscow. 111123, Russian Federation, Moscow, sh. Entuziastov, d. 86;
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
nane18@list.ru
ГБУЗ «Московский клинический научный центр им. А.С.Логинова» Департамента здравоохранения г. Москвы. 111123, Россия, Москва, ш. Энтузиастов, д. 86;
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1
nane18@list.ru
________________________________________________
A.S.Loginov Moscow Clinical Scientific Practical Center of the Department of Health of Moscow. 111123, Russian Federation, Moscow, sh. Entuziastov, d. 86;
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
nane18@list.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.